Research progress on the relevance of HR-HPV load and cervical precancerous lesions and cervical cancer

doi:10.3760/cma.j.issn.1007-1245.2024.06.010

Abstract

Abstract:

Cervical cancer is the fourth most common cancer worldwide, and its incidence is rising. The most important risk factor for cervical cancer is persistent high risk human papilloma virus (HR-HPV) infection. Many authorities in the world have recommended that HPV DNA testing has been a method of cervical cancer preliminary screening since 2019. However, this method screens out a large number of HPV-positive women, so it is necessary to accurately identify the high-risk groups of cervical cancer and implement effective managements. Recent studies have shown that HR-HPV load may be a reference marker for the progression of cervical lesions, but the relationship between them is still not clear. The aim of this study is to investigate the relevance of HR-HPV load and cervical precancerous lesions and cervical cancer, and to improve the early diagnosis and treatment of cervical cancer.

Key words:

High risk human papilloma virus, HR-HPV load, Cervical intraepithelial neoplasia, Cervical cancer, Progress

摘要：

宫颈癌为全球第四大恶性肿瘤，且发病率正在不断上升。高危型人乳头瘤病毒（high risk human papilloma virus，HR-HPV）持续感染被认为是宫颈癌的主要致病因素。自2019年开始，很多权威机构都建议采用HPV DNA检测作为宫颈癌初筛手段。但是，这种方法会筛查出大量HPV阳性的女性，因此，准确识别宫颈癌高风险人群，并实施有效的管理很有必要。近来有研究表明，HR-HPV可能是宫颈病变病情进展的一个参考指标，但它们之间的关系仍不明确。因此，本文旨在深入探讨HR-HPV载量与宫颈病变严重程度之间的关系，以期有助于宫颈癌的早期诊断和早期治疗。

关键词:

高危型人乳头瘤病毒, 病毒载量, 宫颈上皮内病变, 宫颈癌, 进展

Chen Xiaolin, Yang Zhen.

Research progress on the relevance of HR-HPV load and cervical precancerous lesions and cervical cancer [J]. International Medicine and Health Guidance News, 2024, 30(6): 932-935.

陈晓琳, 杨贞.

HR-HPV载量与宫颈上皮内病变及宫颈癌相关性的研究进展 [J]. 国际医药卫生导报, 2024, 30(6): 932-935.

References

[1] World Health Organization. International Agency for Research on Cancer. 160-China-fact-sheets.2020[R/OL].(2021-03-01)[2022-08-08]. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf.
[2] World Health Organization. International Agency for Research on Cancer. 23-Cervix-uteri-fact-sheet.2020[R/OL]. (2021-03-01)[2022-08-08]. https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf.
[3] 王鹏,郭珍,赵冬梅,等. 高危型HPV分型检测对早期宫颈癌诊断的意义[J]. 中华医学杂志,2020,100(18): 1396-1400. DOI: 10.3760/cma.j.cn112137-20191024-02313.
[4] Buick C, Murphy KJ, Howell D, et al. Understanding the role of oncogenic human papillomavirus (HPV) status on adherence behaviors among women with abnormal cervical cytology[J]. BMC Womens Health, 2021, 21(1):29. DOI: 10.1186/s12905-020-01168-2.
[5] 王悦,王轶英,谢幸,等. HPV分型与定量检测在子宫颈癌筛查中的作用及意义[J]. 中华妇产科杂志,2019,54(5):350-353. DOI:10.3760/cma.j.issn.0529- 567x.2019.05.012.
[6] Luo H, Belinson JL, Du H, et al. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening[J]. J Low Genit Tract Dis, 2017, 21(1): 12-16. DOI: 10.1097/LGT.0000000000000277.
[7] Dong L, Wang MZ, Zhao XL, et al. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study[J]. Gynecol Oncol, 2018, 148(1):103-110. DOI: 10.1016/j.ygyno.2017.11.016.
[8] Cao M, Wang Y, Wang D, et al. Increased high-risk human papillomavirus viral load is associated with immunosuppressed microenvironment and predicts a worse long-term survival in cervical cancer patients[J]. Am J Clin Pathol, 2020, 153(4): 502-512. DOI: 10.1093/ajcp/aqz186.
[9] Chan PK, Lam CW, Cheung TH, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer[J]. J Natl Cancer Inst, 2002, 94(16): 1249-1253. DOI: 10.1093/jnci/94.16.1249.
[10] Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis[J]. Br J Cancer, 2003, 88(1): 63-73. DOI: 10.1038/sj.bjc.6600688.
[11] Bruni L, Serrano B, Mena M, et al. Human papillomavirus and related diseases in the world,in summary report 2 February 2022[R/OL].[2022-04-10]. Barcelona: ICO/IARC information centre on HPV and cancer (HPV Information Centre)
[12] 中共中央,国务院. "健康中国2030"规划纲要[A/OL].(2016-10-25)[2022-04-10]. https://health.huanqiu.com/article/9CaKrnJYhH7
[13] 魏丽惠. 子宫颈癌筛查——从细胞学检查到HPV检测[J]. 中华妇产科杂志,2019,54(5):289-292. DOI:10.3760/cma.j.issn.0529-567x.2019.05.001.
[14] 单玮,张涛,张铁军,等. 我国女性人乳头瘤病毒(HPV)感染的流行病学现状[J]. 中华疾病控制杂志,2017,21(1):89-93. DOI: 10.16462/j.cnki.zhjbkz.2017.01.021.
[15] Camporiondo MP, Farchi F, Ciccozzi M, et al. Detection of HPV and co-infecting pathogens in healthy Italian women by multiplex real-time PCR[J]. Infez Med, 2016, 24(1):12-17.
[16] Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology[J]. JAMA, 2002, 287(16): 2114-2119. DOI: 10.1001/jama.287.16.2114.
[17] Sun Z, Zhang R, Liu Z, et al. Development of a fluorescence-based multiplex genotyping method for simultaneous determination of human papillomavirus infections and viral loads[J]. BMC Cancer, 2015, 15: 860. DOI: 10.1186/s12885-015-1874-9.
[18] 张丽芳,欧阳小娟,余英豪,等. 人乳头瘤病毒多基因亚型与病毒载量同步检测在子宫颈病理诊断中的应用[J]. 临床与实验病理学杂志,2022,38(3):350-353. DOI:10.13315/j.cnki.cjcep.2022.03.022.
[19] 孔蕊,姚群,吴晓博,等. 高危型人乳头状瘤病毒感染类型及载量与子宫颈癌前病变严重程度及病变范围的相关性[J/CD]. 中华临床医师杂志(电子版),2020,14(5):376-379. DOI:10.3877/cma.j.issn.1674-0785.2020.05.011.
[20] 徐小倩,张莉,胡尚英,等. HPV载量在阴道镜下随机活检中的作用分析[J]. 中华预防医学杂志,2018,52(5):475-479. DOI:10.3760/cma.j.issn.0253-9624.2018.05.005.
[21] 赵方辉,胡尚英,王少明,等. 高危型人乳头瘤病毒载量与子宫颈病变的关系[J]. 中华预防医学杂志,2009,43(7):565-570. DOI:10.3760/cma.j.issn.0253-9624.2009. 07.008.
[22] Dong L, Wang MZ, Zhao XL, et al. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: a prospective screening cohort study[J]. Gynecol Oncol, 2018, 148(1): 103-110. DOI: 10.1016/j.ygyno.2017.11.016.
[23] Zhao X, Zhao S, Hu S, et al. Role of human papillomavirus DNA load in predicting the long-term risk of cervical cancer: a 15-year prospective cohort study in China[J]. J Infect Dis, 2019, 219(2):215-222. DOI: 10.1093/infdis/jiy507.
[24] Manawapat-Klopfer A, Wang L, Haedicke-Jarboui J, et al. HPV16 viral load and physical state measurement as a potential immediate triage strategy for HR-HPV-infected women: a study in 644 women with single HPV16 infections[J]. Am J Cancer Res, 2018, 8(4):715-722.
[25] Malagón T, Louvanto K, Ramanakumar AV, et al. Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age[J]. Gynecol Oncol, 2019, 155(2): 245-253. DOI: 10.1016/j.ygyno.2019.09.010.
[26] Constandinou-Williams C, Collins SI, Roberts S, et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(3): 832-837. DOI: 10.1158/1055-9965.EPI-09-0838.
[27] 庄加梅. 探讨高危型HPV亚型与病毒载量检测对宫颈癌筛查的效果[J]. 中外女性健康研究,2023,31(2):87-89.
[28] 邓振宇,许红岩. 高危型HPV病毒载量及组织中miR-143表达与宫颈癌发病的关系研究[J]. 国际医药卫生导报,2020,26(24):3794-3797. DOI:10.3760/cma.j.issn. 1007-1245.2020.24.021.
[29] 邵招凤,戚秀秀,杨玲飞,等. 宫颈上皮内瘤变患者感染高危型人乳头瘤病毒载量水平及临床意义[J]. 中华医院感染学杂志,2021,31(22):3453-3457. DOI:10.11816/cn.ni.2021- 210107.
[30] Fu Xi L, Schiffman M, Ke Y, et al. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18[J]. Int J Cancer, 2017, 140(8): 1747-1756. DOI: 10.1002/ijc.30594.
[31] 陈香,董燕,张丽.宫颈高级别鳞状上皮内病变锥切术后高危型HPV持续感染的研究进展[J].实用医学杂志,2021,37(16):2039-2043. DOI:10.3969/j.issn.1006-5725.2021. 16.001.
[32] Wang W, Zhang XH, Li M, et al. Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical cancer[J]. Clin Chim Acta, 2018, 483: 249-255. DOI: 10.1016/j.cca.2018.05.016.
[33] Badaracco G, Venuti A, Sedati A, et al. HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness[J]. J Med Virol, 2002, 67(4): 574-582. DOI: 10.1002/jmv.10141.
[34] Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)[J]. Br J Cancer, 2005, 92(12): 2195-2200. DOI: 10.1038/sj.bjc.6602648.
[35] Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer[J]. Lancet, 2002, 360(9328): 228-229. DOI: 10.1016/S0140-6736(02)09463-1.
[36] Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer[J]. Am J Obstet Gynecol, 2004, 191(5):1590-1597. DOI: 10.1016/j.ajog.2004.05.018.
[37] 祁德波,张丽冉,赵东曼,等. 高危型HPV病毒载量与不同宫颈病变的相关性分析[J]. 检验医学与临床,2019,16(15):2127-2130,2133. DOI:10.3969/j.issn.1672-9455.2019. 15.005.
[38] Trevisan A, Schlecht NF, Ramanakumar AV, et al. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance[J]. J Gen Virol, 2013, 94(Pt 8): 1850-1857. DOI: 10.1099/vir.0.051722-0.
[39] Luo H, Belinson JL, Du H, et al. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening[J]. J Low Genit Tract Dis, 2017, 21(1): 12-16. DOI: 10.1097/LGT.0000000000000277.